Yep I just did today as well. Risk-reward looks great to me. Downside is limited by $4/share in cash and dramatically reduced burn now that Salix is funding all Relistor costs going forward. There's reason to believe the Relistor ship may be righted under Salix. We get essentially a free shot on goal this week with the Phase 1 PSMA drug data coming out (don't think the market is assigning hardly any value to the drug so if positive news we might get a quick jump in share price). And there's still a few earlier stage drugs for PGNX, namely the mTor/PI3K/MNK inhibitor that sounds interesting. Good luck to us both.
I'm still waiting to add one more biotech. I'm going to be real picky about this last one as I may not have any new funds to add for awhile.
News 
Market Data 
Discover 
